tbuckley/cabot-search huggingface dataset:
<i>Tbx2a</i>Modulates Switching of<i>RH2</i>and<i>LWS</i>Opsin Gene Expression
Authors: Benjamin A Sandkam, Laura Campello, Conor O’Brien, Sri Pratima Nandamuri, William J Gammerdinger, Matthew A Conte, Anand Swaroop, Karen L Carleton
Journal: Molecular Biology and Evolution (2020)

Abstract Sensory systems are tuned by selection to maximize organismal fitness in particular environments. This tuning has implications for intraspecies communication, the maintenance of species boundaries, and speciation. Tuning of color vision largely depends on the sequence of the expressed opsin proteins. To improve tuning of visual sensitivities to shifts in habitat or foraging ecology over the course of development, many organisms change which opsins are expressed. Changes in this developmental sequence (heterochronic shifts) can create differences in visual sensitivity among closely related species. The genetic mechanisms by which these developmental shifts occur are poorly understood. Here, we use quantitative trait locus analyses, genome sequencing, and gene expression studies in African cichlid fishes to identify a role for the transcription factor Tbx2a in driving a switch between long wavelength sensitive (LWS) and Rhodopsin-like (RH2) opsin expression. We identify binding sites for Tbx2a in the LWS promoter and the highly conserved locus control region of RH2 which concurrently promote LWS expression while repressing RH2 expression. We also present evidence that a single change in Tbx2a regulatory sequence has led to a species difference in visual tuning, providing the first mechanistic model for the evolution of rapid switches in sensory tuning. This difference in visual tuning likely has important roles in evolution as it corresponds to differences in diet, microhabitat choice, and male nuptial coloration.
Gal d 7—a major allergen in primary chicken meat allergy
Authors: Christoph Klug, Wolfgang Hemmer, Patricia Román-Carrasco, Margarete Focke-Tejkl, Santiago Quirce, Teresa Boyano-Martínez, Erwin Gaubitzer, Herbert Wank, Ines Swoboda
Journal: Journal of Allergy and Clinical Immunology (2020)

Poultry meat can induce severe allergic reactions. So far, the molecules causing poultry meat allergy are largely unknown.Our aim was to identify and characterize poultry meat allergens.Profiles of patients' IgE reactivity to chicken muscle were analyzed in immunoblots, and proteins recognized by the majority of patients were subjected to peptide mass fingerprinting. A 23-kDa IgE-reactive protein was identified as myosin light chain 1, designated Gallus domesticus 7 (Gal d 7). Recombinant Gal d 7 was produced in Escherichia coli. The protein's IgE reactivity was analyzed in ELISA experiments, and cross-reactivity with allergens of other poultry species was assessed in inhibition immunoblots. Fold and thermal stability were evaluated by circular dichroism analysis, and enzymatic stability was investigated using in vitro gastrointestinal digestion assays.Recombinant Gal d 7 represents a properly folded, predominantly α-helical protein and displays IgE-binding activity comparable to that of its natural counterpart. IgE reactivity analysis in 28 patients allergic to chicken meat revealed that Gal d 7 is a major allergen for patients primarily sensitized to chicken meat. Furthermore, Gal d 7-cross-reactive allergens were also detected in other poultry species, suggesting that recombinant Gal d 7 can be used as a diagnostic marker allergen for poultry meat allergy. The high thermal stability, refolding capacity, and resistance to gastrointestinal enzymes might explain why Gal d 7 can act as a potent sensitizing agent.Gal d 7 represents a novel major chicken meat allergen. Recombinant Gal d 7 could be used for diagnosis of genuine poultry meat sensitization.
Effects of potassium fertilization on population build up of rice stem borers (lepidopteron pests) and rice (Oryza sativa L.) yield
Authors: Muhammad Sarwar
Journal: Journal of Clinical Oncology (2012)

The effects of potassium (K) application rates on population build up of rice stem borers and rice yield were evaluated using cultivar “Shua-92”. The treatments were consisted of K applications at 40, 50 and 60 kg/ha at the top dressing, andno K fertilizer application along with normal doses of nitrogen and phosphorous.The results showed that compared with the untreated control, K fertilizer significantly reduced the rate of rice borers’ infestation and increased paddy yield. The treatments 50 and 60 kg K significantly reduced the incidence of pest and increased the grain yield of rice, but none significantly followed by application at 40 kg compared to control treatment. This assures that at low level of K application, biomass of rice plants were significantly less than the plants grown in the higher levels, but, further increase in the amount of K from 50 to 60 kg/ha did not significantly increase the pest growth and biomass of rice plants. Based on observations, it is possible to make sure that by considering cost benefit ratio application of K by adopting the rate of 50 kg/ha might be the most effective strategy in inhibiting rice pest’s incidence. The results suggest that application of K fertilizer could be useful in the recovery of plants damage when attacked by larvae of borers which can be safely and successfully managed to contribute larger volume of yield and reduce the environmental pollution.

 

	Key words: Plant nutrition, K fertilizer, herbivore, insect pests, rice, Oryza sativa.
IMPACT OF MEMBRANOUS SEPTAL LENGTH ON NEW PERMANENT PACEMAKER IMPLANTATION AFTER SAPIEN 3 TAVR
Authors: Syed Zaid, Aditya Sengupta, Melissa Tsoi, Asaad Khan, Hasan Ahmad, Joshua Goldberg, George D. Dangas, Samin K. Sharma, Annapoorna Subhash Kini, Gilbert Tang
Journal: Journal of the American College of Cardiology (2020)
Co-occurrence of Merkel Cell Carcinoma and Chronic Inflammatory Demyelinating Polyneuropathy
Authors: Alyce Mei-Shiuan Kuo, Christopher Andrew Barker
Journal: JAMA Dermatology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
BEHAVIORAL FACTORS AS MEDIATORS OF THE IMPACT OF EDUCATIONAL ATTAINMENT ON INCIDENT HEART FAILURE: A MEDIATION ANALYSIS
Authors: Lin Yifen, Zhang Shaozhao, Zhong Xiangbin, Li Yuqi, Sun Xiuting, Huang Yiquan, Fan Yongqiang, Guo Yue, Xiong Zhenyu, Zhou Huimin, Liu Menghui, Xu Xingfeng, Yang Daya, Zhuang Xiaodong, Liao Xinxue
Journal: Journal of the American College of Cardiology (2020)
RIVAROXABAN IN COMBINATION WITH ANTIARRHYTHMIC DRUGS DOES NOT INCREASE THE BLEEDING RISKS IN PATIENTS WITH NON-PERMANENT ATRIAL FIBRILLATION
Authors: Wei-Ru Chiou, Jen-Yu Chuang, Chun-Che Huang, Po-Lin Lin, Ying-Hsiang Lee
Journal: Journal of the American College of Cardiology (2020)
THE IMPACT OF CONTRAST-INDUCED NEPHROPATHY ON LONG-TERM MORTALITY IN ELDERLY PATIENTS AFTER CORONARY ANGIOGRAPHY
Authors: Wei Guo, Jin Liu, Zhaodong Guo, Li Lei, Bowen Liu, Shiqun Chen, Feier Song, Guoli Sun, Huixia Liu, Yong Liu
Journal: Journal of the American College of Cardiology (2020)
Real-life assessment of chronic rhinosinusitis patients using mobile technology
Authors: SF Seys, S De Bont, J Bousquet, Claus Bachert, WJ Fokkens, I Agache, M Bernal-Sprekelsen, I Callebaut, L Cardell, S Carrie, P Castelnuovo, R Cathcart, J Constantinidis, L Cools, M Cornet, G Clement, JC De Sousa, T Cox, L Deneyer, M Doulaptsi, Philippe Gevaert, C Hopkins, T Hummel, W Hosemann, R Jacobs, M Jorissen, BN Landis, A Leunig, Lund, G Mariën, J Mullol, M Onerci, S Palkonen, I Proano, E Prokopakis, D Ryan, H Riechelmann, C Segboer, K Speleman, A Steinsvik, P Surda, P Tomazic, O Vanderveken, L Van Gerven, Thibaut Van Zele, B Verhaeghe, K Vierstraete, S Vlaminck, B Pugin, Peter Hellings
Journal: Allergy (2019)
Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)
Authors: R. M. Bukowski, F. Kabbinavar, R. A. Figlin, K. Flaherty, S. Srinivas, U. Vaishampayan, H. Drabkin, J. Dutcher, F. Scappaticci, D. McDermott
Journal: Journal of Clinical Oncology (2006)

4523 Background: Bevacizumab (B) has clinical efficacy in metastatic RCC following cytokine treatment. A single-arm Phase II trial suggested potential clinical benefit of adding erlotinib (E) to B. To further assess this combination in RCC, we conducted a multicenter, randomized, double-blind Phase 2 trial comparing B+E vs B + placebo. Methods: Eligibility criteria included: previously untreated metastatic RCC with &gt;50% clear cell histology; previous nephrectomy; ECOG PS 0 or 1; measurable disease; serum Ca++ ≤ 10 mg/dL; LDH ≤ 1.5 ULN; Hgb ≥ 9 g/dL; and standard exclusion criteria for B. All pts received B 10 mg/kg IV q 2 wk with either E 150 mg po daily or placebo until disease progression or unacceptable toxicity. Tumors were assessed using RECIST every 8 wks. A landmark analysis was performed 9 mo after accrual of the last pt. Objective response rate (ORR) and progression-free survival (PFS) were co-primary endpoints. Secondary endpoints included response duration, overall survival, and safety. Results: 104 pts (53 B, 51 B+E) were enrolled at 20 sites from Mar 2004–Oct 2004. 65 pts have discontinued therapy. 55 have progressed (PFS HR = 0.86, CI 0.5, 1.49). Median follow-up was 9.8 mo. Median survival duration was not reached. Only 1 treatment-related death due to GI perforation occurred (on B+E). Updated safety and survival data will be presented. Conclusions: B+E and B were well tolerated. Adding E does not appear to improve efficacy from B. PFS of 8.5 months with B compares favorably with the historical PFS of ∼ 4.7 mo with interferon alpha (IFN). Results of phase III trials comparing IFN ± B are pending. [Table: see text] [Table: see text]
HSR20-083: Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the U.S.
Authors: Kaushal Desai, Gillian Hooker, Gboyega Adeboyeje, Sumesh Kachroo, Shuvayu Sankar Sen
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-083: Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests Among Cancer Patients in the U.S." published on 20 Mar 2020 by National Comprehensive Cancer Network.
EFFECTS OF EARLY INTRAPERICARDIAL DELIVERY OF MICROVESICLES OBTAINED FROM HEART-DERIVED CELLS IN CARDIAC FUNCTION IN AN EXPERIMENTAL MYOCARDIAL INFARCTION IN SWINE
Authors: Veronica Crisostomo Ayala, Virginia Blanco Blázquez, Claudia Baez-Diaz, Javier Casado, Esther Lopez-Nieto, Irene Gonzalez-Bueno, Ana Abad Cobo, Antoni Bayes-Genis, Carolina Gálvez-Montón, Francisco Sanchez
Journal: Journal of the American College of Cardiology (2020)
SHARED DECISION MAKING AND PATIENT REPORTED OUTCOMES AMONG ADULTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, MEDICAL EXPENDITURE PANEL SURVEY 2006-2015
Authors: Victor Okunrintemi, Javier Valero-Elizondo, None Texas, Neil Stone, Ron Blankstein, Michael Blaha, Martha Gulati, Salim Virani, William Zoghbi, Erin Michos, Khurram Nasir
Journal: Journal of the American College of Cardiology (2020)
BPI20-017: Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R model, 4R = Right Information / Care / Patient / Time
Authors: Della F. Makower, Christine Brezina Weldon, Julia R. Trosman, Kent Hoskins, Cathleen Schaeffer, Bruce D. Rapkin, Melissa A. Simon, Al B. Benson, William J. Gradishar
Journal: Journal of the National Comprehensive Cancer Network (2020)

"BPI20-017: Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R model, 4R = Right Information / Care / Patient / Time" published on 20 Mar 2020 by National Comprehensive Cancer Network.
What can we glean from linking registry and Medicaid claims data?
Authors: D. Schrag, B. Virnig, F. Xu, M. Allen, J. L. Warren
Journal: Journal of Clinical Oncology (2006)

6055 Background: Cancer quality of care problems are concentrated among the indigent. Although Medicare claims linked to tumor registry data have become an important source for evaluating cancer care, parallel efforts to use Medicaid claims are not well developed. Objective: To evaluate the feasibility and potential value of linking the California state cancer registry with Medicaid claims for health services research. Methods: Cases reported to the California Cancer Registry (CCR) between 1988 and 2000 were matched with California Medicaid enrollment and claims data. We assessed the number of cancer cases that appeared in the Medicaid enrollment data. We evaluated the sensitivity of Medicaid claims to capture cancer diagnoses and treatments reported in the registry data. Results: 6,800 patients ages 18–64 had records in the 1998 CCR data that were matched to the 1998 Medicaid enrollment file; Medicaid enrollees accounted for 34.4% of patients with hepatoma and 21.1% of patients with cervix cancer, but only 8.9% of breast and 8.9% of testicular cancer patients in this age bracket. Medicaid data had only modest sensitivity to capture cancer diagnoses and procedures. For 5 cancers, Medicaid claims included procedure codes for about 70% of surgeries reported in the registry data. Missing diagnoses and procedures could be attributed to discontinuous enrollment, Medicare crossover and enrollment in pre-paid health plans. Conclusion: Linkage of CCR and Medicaid enrollment data identified sizable populations of indigent patients. However, the modest sensitivity of Medicaid claims to capture cancer diagnoses and procedures currently limits the utility of Medicaid data to assess cancer treatment and outcomes. No significant financial relationships to disclose.
In-hospital and long-term outcomes in patients with malignancy undergoing percutaneous endoscopic gastrostomy (PEG).
Authors: Emily Zhi-Yun Keung, Xiaoxia Liu, Afrin Nuzhad, Guilherme Rabinowits, Vihas Patel
Journal: Journal of Clinical Oncology (2012)

9086 Background: PEG is widely performed in cancer patients as a means of providing nutrition or palliation. Although considered safe, PEG-associated outcomes in these patients remain poorly described. We examined the safety and benefits of PEG placement in this patient population. Methods: A five year retrospective review of all patients with malignancy (excluding head/neck, thoracic) who underwent attempted PEG at our institution was performed. Results: PEG was placed in 187 of 189 patients; 64 with hematologic malignancy (H-M), 125 non-hematologic malignancy (NH-M). Median age at time of PEG was 60.8 years. Indication was nutritional support (100%) in H-M, enteral access (59.2%) and management of obstructive symptoms (38.4%) in NH-M. A minority were able to return home (27.5%), discontinue parenteral nutrition (22%), advance diet for nutrition (24.6%) or comfort (17.1%) with the rest remaining NPO. Overall rates of PEG-related major (aspiration, tube dislodgement/leakage, bleeding, visceral injury, respiratory failure after procedure, cardiac arrest) and minor (superficial infection, ileus) complications were 21.4% and 11.3%, respectively, with higher rates in H-M (34.4% and 20.3% vs 14.4% and 6.4%). All cause in-hospital mortality was high: 31.3% H-M, 13.6% NH-M. Median time from PEG placement to death was 54 days. Leading cause of death differed by malignancy: respiratory failure and sepsis in H-M (31% and 21%), primary malignancy in NH-M (75%). Overall one year mortality was 56%. Code status was changed in 21% of patients after PEG (“Full Code” to “Do Not Resuscitate/Do No Intubate” or “Comfort Measures Only”). Multivariate/subgroup analyses will be presented at time of meeting. Conclusions: PEG placement in this study population was associated with significant procedure-related complications and failed to achieve TPN independence or advancement of diet. Nearly 25% of patients declined aggressive resuscitation strategies after undergoing surgery for PEG. Thus, higher burden of counseling is needed to carefully weigh the risk and benefit of PEG placement in these patients. Further studies are needed to elucidate the factors affecting the decision process and patient selection.
Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy
Authors: Tanner Dalton, Ekaterina Doubrovina, Dmitry Pankov, Raymond Reynolds, Hanna Scholze, Annamalai Selvakumar, Teresa Vizconde, Bhumesh Savalia, Vadim Dyomin, Christoph Weigel, Christopher C. Oakes, Alicia Alonso, Olivier Elemento, Heng Pan, Jude M. Phillip, Richard J. O’Reilly, Benjamin E. Gewurz, Ethel Cesarman, Lisa Giulino-Roth
Journal: Blood (2020)
PROGNOSIS OF SHORT-TERM (3-MONTH) VERSUS STANDARD (12-MONTH) DUAL ANTI-PLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME TREATED WITH PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Mohamed Elmassry, Wasawat Vutthikraivit, Saif El-Nawaa, Pablo Paz, M. Rubayat Rahman, John Abdelmalek, Barbara Mantilla, Ahmed Souka, Scott Shurmur
Journal: Journal of the American College of Cardiology (2020)
Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations
Authors: N. Sunaga, N. Yanagitani, K. Kaira, Y. Tomizawa, H. Iijima, Y. Otani, S. Tanaka, T. Suga, K. Dobashi, M. Mori
Journal: Journal of Clinical Oncology (2006)

7183 Purpose: Recent studies have indicated that the mutations of epidermal growth factor receptor (EGFR) were associated with sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR tyrosine kinase inhibitor. The clinical objective of this study was to prospectively evaluate the efficacy of gefitinib in patients with stageIII/IV NSCLC that had the EGFR mutations. Methods: Genomic DNA was extracted from tumor specimens and EGFR mutations in exon 19 and 21 were analyzed by direct sequencing. Patients with stageIII/IV NSCLC who had the EGFR mutations were treated with gefitinib (250mg) orally. Response, survival data and toxicity were assessed. Results: From Nov. 2004 to Dec 2005, 14 patients with the EGFR mutations received gefitinib (median age: 67 years; 2 males, 12 females; 1 smokers, 13 non-smokers; all adenocarcinomas). Two patients discontinued gefitinib and came off study because of interstitial pneumonitis (grade 3) and acne (grade 3), respectively. Response data are available for 12 patients. Two achieved a complete response (CR), seven exhibited a partial response (PR) and three had stable disease (SD). Response rate and disease control rate were 75% and 100%, respectively. There were no grade 3/4 toxicities in these 12 patients. All patients were alive during median follow-up period of 8 months (range 1–13 months). Conclusions: The EGFR mutations could be an excellent predictor of response to gefitinib in NSCLC. No significant financial relationships to disclose.
Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease
Authors: Dave Singh, Mona Bafadhel, Christopher E. Brightling, Frank C. Sciurba, Jeffrey L. Curtis, Fernando J. Martinez, Cara B. Pasquale, Debora D. Merrill, Norbert Metzdorf, Stefano Petruzzelli, Ruth Tal-Singer, Christopher Compton, Stephen Rennard, Ubaldo J. Martin
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
ANALYSIS OF ELEVATED LIPOPROTEIN (A) LEVELS IN A REFERRAL CARDIOVASCULAR CENTER IN SAO PAULO, BRAZIL
Authors: Marjorie Hayashida Mizuta, Marcio Hiroshi Miname, Viviane Z. Rocha, Ana Paula M. Chacra, Wilson Salgado, Raul D. Santos
Journal: Journal of the American College of Cardiology (2020)
THE IMPACT OF VENTRICULAR-ARTERIAL COUPLING AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT ON MID-TERM CLINICAL OUTCOMES
Authors: Hiroaki Yokoyama, Futoshi Yamanaka, Koki Shishido, Tomoki Ochiai, Shohei Yokota, Yusuke Watanabe, Shinichi Shirai, Norio Tada, Motoharu Araki, Fumiaki Yashima, Toru Naganuma, Hiroshi Ueno, Minoru Tabata, Kazuki Mizutani, Akihiro Higashimori, Kensuke Takagi, Masanori Yamamoto, Shigeru Saito, Kentaro Hayashida
Journal: Journal of the American College of Cardiology (2020)
VERY LATE PRESENTATION OF FULMINANT MYOCARDIAL IMMUNE-RELATED TOXICITY IN A PATIENT ON PEMBROLIZUMAB
Authors: Mahmoud Ali, Marc Atzenhoefer, Kevin Bodker, Tarek Ajam, Daniel Johnsrud, Zeinab Saleh, Adil Wani, Patrycja Galazka, Tanvir Bajwa, M. Fuad Jan
Journal: Journal of the American College of Cardiology (2020)
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma.
Authors: Otto Metzger Filho, Anita Giobbie-Hurder, Elizabeth A Mallon, Giuseppe Viale, Eric P. Winer, Beat J. K. Thurlimann, Richard D. Gelber, Meredith M. Regan, Marco Colleoni, Bent Ejlertsen, Herve Bonnefoi, John F. Forbes, Patrick Neven, Andrew M. Wardley, Istvan Lang, Ian E. Smith, Karen N. Price, Alan S. Coates, Aron Goldhirsch
Journal: Journal of Clinical Oncology (2013)

529 Background: BIG 1-98 is a randomized, phase III study that compares five years of tamoxifen (tam) or letrozole (let), (monotherapy arms), or their sequences (tam-let or let-tam) in post-menopausal women with ER+ early BC. In the monotherapy arms, the magnitude of benefit of adjuvant let compared with tam varies by histology (greater in invasive lobular carcinoma (ILC) than invasive ductal carcinoma (IDC)). In this analysis we investigate the magnitude of benefit of let compared to tam-let and let-tam according to histology (IDC and ILC) at 96 months of median follow-up. Methods: There were 4,634 patients enrolled in the let, tam-let and let-tam arms of BIG-98. This analysis includes patients with centrally-reviewed histological subtype (n=4,223); classified as classic ILC or IDC (n=3,790); and with centrally reviewed ER, PgR and Ki67 (n=3,212). Results: The 8-year DFS and OS univariate estimates (±SE) for IDC and ILC are presented in the Table. When correcting for classic clinicopathological variables, treatment assignment was not a significant predictor of DFS and OS. Conclusions: We observed a trend toward greater magnitude of benefit in favor of let monotherapy for ILC than IDC. In the ILC subset, improvements for both DFS and OS were seen for let when compared to tam-let or let-tam, though not statistically significant. This may be due to the reduced number of ILC patients across subgroups. The present analysis is consistent with previous data from the monotherapy arms where let was associated with better DFS and OS than tam for ILC, and suggests that let might be the preferred upfront regimen for patients diagnosed with ILC. Clinical trial information: NCT00004205. [Table: see text]